+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Lomustine"

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024 - Product Thumbnail Image

Glioblastoma Multiforme (GBM) Treatment Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
Brain Tumor Therapeutics: Global Markets to 2023 - Product Thumbnail Image

Brain Tumor Therapeutics: Global Markets to 2023

  • Report
  • December 2018
  • 161 Pages
  • Global
From
From
US Glioma - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

US Glioma - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • April 2023
  • 200 Pages
  • United States
From
From
From
From
  • 9 Results (Page 1 of 1)
Loading Indicator

Lomustine is a chemotherapy drug used to treat brain cancer. It is a nitrosourea, a type of alkylating agent, and works by interfering with the growth of cancer cells. It is used to treat a variety of brain tumors, including glioblastoma, anaplastic astrocytoma, and medulloblastoma. It is also used to treat other types of cancer, such as Hodgkin's lymphoma and non-Hodgkin's lymphoma. Lomustine is available in both oral and intravenous forms. It is usually given in combination with other chemotherapy drugs, such as temozolomide or carboplatin. The drug is generally well tolerated, but can cause side effects such as nausea, vomiting, and hair loss. The market for lomustine is highly competitive, with several companies offering the drug. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, and Novartis. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of the drug. Show Less Read more